07 September 2020 : Clinical Research
Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy
Xianghua Zeng123CDEG, Shicong Zhu12BCD, Cheng Xu4CF, Zhongyu Wang12CD, Xingxing Su12CD, Dong Zeng12CD, Haixia Long12AF*, Bo Zhu12AGDOI: 10.12659/MSM.922576
Med Sci Monit 2020; 26:e922576
Table 5 Incidence of immune-related adverse events in all recipients of PD1 inhibitors.
| Events | All (n=66) | CCI | SCS | ||
|---|---|---|---|---|---|
| <1 (n=38) | ≥1 (n=28) | <8 (n=41) | ≥8 (n=25) | ||
| All | 20 (30.3%) | 10 (26.3%) | 10 (35.7%) | 13 (31.7%) | 7 (28.0%) |
| Skin rash | 6 (9.1%) | 5 (13.2%) | 1 (3.6%) | 3 (7.3%) | 3 (12.0%) |
| Pneumonitis | 6 (9.1%) | 3 (7.9%) | 3 (10.7%) | 5 (12.2%) | 1 (4.0%) |
| Hypothyroidism | 4 (6.1%) | 1 (2.6%) | 3 (10.7%) | 2 (4.9%) | 2 (8.0%) |
| Hepatitis | 3 (4.5%) | 1 (2.6%) | 2 (7.1%) | 2 (4.9%) | 1 (4.0%) |
| Colitis | 1 (1.5%) | 0 | 1 (3.6%) | 1 (2.4%) | 0 |
| PD1 – programmed cell death protein 1; CCI – Charlson comorbidity index; SCS – simplified comorbidity score. | |||||